Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors
Przemysław Czeleń1, Agnieszka Skotnicka2, Beata Szefler1
1Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Kurpinskiego 5, 85-096 Bydgoszcz, Poland.
Abstract:
Tumors are still one of the main causes of death; therefore, the search for new therapeutic agents that will enable the implementation of effective treatment is a significant challenge for modern pharmacy. One of the important factors contributing to the development of neoplastic diseases is the overexpression of enzymes responsible for the regulation of cell division processes such as cyclin-dependent kinases. Numerous studies and examples of already-developed drugs confirm that isatin is a convenient basis for the development of new groups of inhibitors for this class of enzyme. Therefore, in this work, a new group of potential inhibitors of the CDK2 enzyme, utilizing isatin derivatives and substituted benzoylhydrazines, has been designed based on the application of computational chemistry methods, such as docking and molecular dynamics, and their inhibiting ability was assessed. In the cases of the selected compounds, a synthesis method was developed, and the selected physicochemical properties of the newly synthesized derivatives were estimated. As part of the completed project, new compounds are developed which are potential inhibitors of the CDK2 enzyme.
Insights
Researchers designed new potential inhibitors for cyclin-dependent kinase 2 (CDK2) using isatin derivatives. These compounds show promise for cancer therapy by targeting cell division regulation.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Oncology
Background:
- Cancer remains a leading cause of mortality, necessitating novel therapeutic strategies.
- Overexpression of cyclin-dependent kinases (CDKs), regulators of cell division, contributes to neoplastic disease development.
- Isatin derivatives have demonstrated utility as a scaffold for developing enzyme inhibitors.
Purpose of the Study:
- To design and evaluate a novel series of potential cyclin-dependent kinase 2 (CDK2) inhibitors.
- To explore the therapeutic potential of isatin derivatives and substituted benzoylhydrazines against CDK2.
Main Methods:
- Computational chemistry techniques, including molecular docking and molecular dynamics simulations, were employed for inhibitor design.
- Synthesis of selected isatin-derived compounds.
- Assessment of the inhibitory potential and physicochemical properties of the newly synthesized derivatives.
Main Results:
- A new group of compounds based on isatin and substituted benzoylhydrazines was designed as potential CDK2 inhibitors.
- Computational methods guided the selection and optimization of candidate molecules.
- Synthesis and preliminary property evaluation of novel potential CDK2 inhibitors were successfully performed.
Conclusions:
- The study successfully developed novel isatin-based compounds with potential as CDK2 inhibitors.
- These findings contribute to the ongoing search for effective anticancer agents targeting cell cycle regulation.
- The designed compounds represent a promising starting point for further development in cancer pharmacotherapy.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
02:39Positive Regulator Molecules
01:26Drug Discovery: Overview